[go: up one dir, main page]

GT200200122A - Imidazotriazinas - Google Patents

Imidazotriazinas

Info

Publication number
GT200200122A
GT200200122A GT200200122A GT200200122A GT200200122A GT 200200122 A GT200200122 A GT 200200122A GT 200200122 A GT200200122 A GT 200200122A GT 200200122 A GT200200122 A GT 200200122A GT 200200122 A GT200200122 A GT 200200122A
Authority
GT
Guatemala
Prior art keywords
imidazotriazinas
parkinson
disease
record
compounds
Prior art date
Application number
GT200200122A
Other languages
English (en)
Inventor
Jens-Kerim Erguden
Marcus Bauser
Nils Burkhardt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200200122A publication Critical patent/GT200200122A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A IMIDAZOTRIAZINAS DE FORMULA GENERAL (I) EN DONDE A, E, R1,R2,R3,R4, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE. ESTOS COMPUESTOS SON UTILES EN PATOLOGIAS NEURODEGENERATIVAS, ESPECIALMENTE DE LA ENFERMEDAD DE PARKINSON.
GT200200122A 2001-06-22 2002-06-17 Imidazotriazinas GT200200122A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10130167A DE10130167A1 (de) 2001-06-22 2001-06-22 Imidazotriazine

Publications (1)

Publication Number Publication Date
GT200200122A true GT200200122A (es) 2003-06-05

Family

ID=7689090

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200200122A GT200200122A (es) 2001-06-22 2002-06-17 Imidazotriazinas

Country Status (11)

Country Link
US (1) US6936609B2 (es)
EP (1) EP1404677A1 (es)
JP (1) JP2004534827A (es)
AR (1) AR036103A1 (es)
CA (1) CA2451525A1 (es)
DE (1) DE10130167A1 (es)
DO (1) DOP2002000429A (es)
GT (1) GT200200122A (es)
PE (1) PE20030129A1 (es)
SV (1) SV2003001107A (es)
WO (1) WO2003000693A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
DE602005023333D1 (de) * 2004-10-15 2010-10-14 Takeda Pharmaceutical Kinaseinhibitoren
US7576080B2 (en) * 2004-12-23 2009-08-18 Memory Pharmaceuticals Corporation Certain thienopyrimidine derivatives as phosphodiesterase 10 inhibitors
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2026813A2 (en) 2006-05-09 2009-02-25 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008030651A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CN103288833B (zh) * 2006-11-22 2018-01-12 因塞特控股公司 作为激酶抑制剂的咪唑并三嗪和咪唑并嘧啶
MX2009010450A (es) 2007-03-27 2009-11-23 Omeros Corp El uso de inhibidores de la fosfodiesterasa 7 para el tratamiento transtornos del movimiento.
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
DE102007032349A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Imidazo-, Pyrazolopyrazine und Imidazotriazine und ihre Verwendung
DE102007060172A1 (de) 2007-12-13 2009-06-25 Bayer Healthcare Ag Triazolotriazine und Triazolopyrazine und ihre Verwendung
DE102008035209A1 (de) 2008-07-29 2010-02-04 Bayer Schering Pharma Aktiengesellschaft Triazolotriazine und Triazolopyrazine und ihre Verwendung
DE102008023801A1 (de) 2008-05-15 2009-11-19 Bayer Schering Pharma Aktiengesellschaft Substituierte Imidazo- und Triazolopyrimidine, Imidazo- und Pyrazolopyrazine und Imidazotriazine
KR101324329B1 (ko) * 2008-09-04 2013-10-31 미쓰비시 타나베 파마 코퍼레이션 삼치환된 피리미딘 화합물 및 ｐｄｅ10 억제제로서의 그의 용도
US20110166135A1 (en) * 2008-09-10 2011-07-07 Hiroshi Morimoto Aromatic nitrogen-containing 6-membered ring compounds and their use
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ES2627703T3 (es) 2010-01-22 2017-07-31 Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii Inhibidores de PI3·quinasa
CA2791166C (en) 2010-02-26 2014-12-30 Mitsubishi Tanabe Pharma Corporation Pyrazolopyrimidine compounds and their use as pde10 inhibitors
US20130131057A1 (en) 2010-05-13 2013-05-23 Centro Nacional De Investigaciones Oncologicas (Cnio New bicyclic compounds as pi3-k and mtor inhibitors
BR112012029994A2 (pt) * 2010-05-28 2019-09-24 Biocryst Pharm Inc composto heterocíclicos como inibidores de janus quinase
JP2014504271A (ja) 2010-11-08 2014-02-20 オメロス コーポレーション Ｐｄｅ７インヒビターを用いる嗜癖および衝動制御障害の処置
US9220715B2 (en) 2010-11-08 2015-12-29 Omeros Corporation Treatment of addiction and impulse-control disorders using PDE7 inhibitors
KR20140009372A (ko) 2011-02-18 2014-01-22 알러간, 인코포레이티드 포스포다이에스테라제 10(pde10a)의 억제제로서의 치환된 6,7-다이알콕시-3-아이소퀴놀리놀 유도체
PH12013501556A1 (en) 2011-02-23 2017-10-25 Pfizer IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
JP2014231475A (ja) * 2011-08-25 2014-12-11 田辺三菱製薬株式会社 新規化合物及びそのｐｄｅ１０阻害薬としての使用
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
NZ708593A (en) 2013-02-27 2018-01-26 Mochida Pharm Co Ltd Novel pyrazole derivative
TN2015000490A1 (fr) 2013-05-02 2017-04-06 Pfizer Dérivés d'imidazo-triazine servant d' inhibiteurs de pde10
US10039764B2 (en) 2013-07-12 2018-08-07 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using PDE10A inhibitors and methods to measure PDE10A expression
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
EP3137454A1 (en) 2014-04-28 2017-03-08 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
CN111825675B (zh) * 2019-04-15 2023-08-01 武汉朗来科技发展有限公司 Rock抑制剂及其制备方法和用途
CN119894518A (zh) 2022-08-18 2025-04-25 米托迪治愈有限责任公司 取代的苯并噁唑和苯并呋喃化合物用于治疗和预防与慢性疲劳、筋疲力尽和/或劳累不耐受相关的疾病的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1457873A (en) * 1973-01-04 1976-12-08 Allen & Hanburys Ltd Imidazotriazines
DK109578A (da) 1977-03-25 1978-09-26 Allen & Hanburys Ltd Fremgangsmaade til fremstilling af heterocycliske forbindelser
IL135462A0 (en) * 1997-11-12 2001-05-20 Bayer Ag 2-phenyl substituted imidazotriazinones as phosphodiesterase inhibitors
AU7766300A (en) * 1999-10-07 2001-05-10 Novaneuron Inc. Gene necessary for striatal function, uses thereof, and compounds for modulatingsame

Also Published As

Publication number Publication date
PE20030129A1 (es) 2003-03-13
AR036103A1 (es) 2004-08-11
SV2003001107A (es) 2003-03-18
EP1404677A1 (de) 2004-04-07
DE10130167A1 (de) 2003-01-02
WO2003000693A1 (de) 2003-01-03
US6936609B2 (en) 2005-08-30
CA2451525A1 (en) 2003-01-03
DOP2002000429A (es) 2003-10-15
US20040249148A1 (en) 2004-12-09
JP2004534827A (ja) 2004-11-18

Similar Documents

Publication Publication Date Title
GT200200122A (es) Imidazotriazinas
GT200400161A (es) Piridinonas sustituidas
GT200300219A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
GT200200286A (es) Nuevos derivados de pirido(2,1-a) isoquinolina
GT200200216A (es) Derivados del 3-azabiciclo [3.1.0] hexano
GT200200013A (es) Derivados de imidazol
GT200200266A (es) Uso de ureas de benzotiazoles
GT200200104A (es) Agentes antibacterianos
GT200300038A (es) Nuevos derivados de piridina y quinolina
GT200200220A (es) Nuevos derivados de pirrolidina
GT200300037A (es) Nuevos derivados de piridina y pirimidina
GT200100146A (es) Activadores de glucoquinasa acetamida benzenica sustituida con atomos de alfa-acilo y alfa-heteroatomo.
GT200300150A (es) Inhibidores de quinasas
CY1113578T1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
GT200300226A (es) 4-piperazinilbencenosulfonilindoles y usos de los mismos
GT200100160A (es) Derivados 4-fenil-piridina.
UY30069A1 (es) Isoxazolinas para controlar plagas de invertebrados
GT200100230A (es) Derivados de benzodiazepina como moduladores del receptor gaba a.
GT200200121A (es) Derivados aromaticos de acidos dicarboxilicos
GT200300072AA (es) Aminoacidos con afinidad por la proteina alfa2delta (solicitud fraccionaria
CY1107956T1 (el) Χρηση υποκατεστημενων 2-αμινοτετραλινιων για την προληπτικη αντιμετωπιση της νοσου του παρκινσον
NO20071476L (no) Antidiuretiske midler.
BRPI0414864A (pt) composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida
GT200100148A (es) Derivados de 4-fenil-piridina.
GT200300284A (es) Derivados de 3h-quinazolin-4-ona